<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05035745</url>
  </required_header>
  <id_info>
    <org_study_id>MC01/05/20; IST-325 (KPT)</org_study_id>
    <nct_id>NCT05035745</nct_id>
  </id_info>
  <brief_title>Selinexor &amp; Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)</brief_title>
  <official_title>Phase I Dose Finding Study of Selinexor and Talazoparib in Patients With Advanced Refractory Solid Tumors, Followed by Phase II Expansion Cohort Study in Patients With Advanced/ Metastatic Triple Negative Breast Cancers. (START)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University Hospital, Singapore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open-label, phase I dose finding study, followed by a phase II&#xD;
      expansion study. Phase I will be carried out in a modified 3+3 dose escalation design, with a&#xD;
      projected enrolment of 33 patients with refractory solid tumors to determine the RP2D. In the&#xD;
      phase II portion, a total of 30 patients with advanced/metastatic TNBC will be enrolled.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis The investigators hypothesize that the combination of Talazoparib and Selinexor&#xD;
      will have clinical efficacy in TNBC, independent of BRCA mutation status.&#xD;
&#xD;
      Primary Objectives&#xD;
&#xD;
        -  To determine the safety profile of combination of Talazoparib and Selinexor in advanced/&#xD;
           metastatic solid tumors.&#xD;
&#xD;
        -  To determine the RP2D of Talazoparib and Selinexor combination therapy in patients with&#xD;
           advanced/ metastatic solid tumors.&#xD;
&#xD;
      Secondary Objectives&#xD;
&#xD;
      • To determine the objective response rate to combination Talazoparib and Selinexor in&#xD;
      advanced/ metastatic TNBCs.&#xD;
&#xD;
      Exploratory Objectives&#xD;
&#xD;
        -  To assess the effect of the combination on pharmacokinetics of Talazoparib and Selinexor&#xD;
&#xD;
        -  To explore the impact of pharmacogenetics on toxicity and efficacy of combination&#xD;
           Talazoparib and Selinexor.&#xD;
&#xD;
        -  To assess changes in circulating tumor cells and plasma biomarkers during treatment.&#xD;
&#xD;
        -  To assess pharmacodynamic changes and predictive biomarkers in tumor tissue during&#xD;
           treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Phase I Patients will be treated with Talazoparib daily and Selinexor once per week (3 out of 4 weeks), on a 4 weekly cycle (28 days) in a modified 3+3 dose escalation/ de-escalation design&#xD;
Phase II Patients with advanced/ metastatic triple negative breast cancer, unselected for known platinum sensitivity or resistance, will be enrolled. A pilot of 10 patients will be enrolled. If 0-1 patients achieve an objective response, the combination is deemed to be of no interest for further development. If 2 or more of 10 patients achieve an objective response, another 20 patients will be enrolled to confirm the objective response rate. In the final objective response analysis, TNBC patients will be stratified into platinum-naïve/platinum sensitive versus platinum-resistant to determine if prior platinum sensitivity impacts objective response rates to the combination of Talazoparib and Selinexor.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety profile of combination of Talazoparib and Selinexor in advanced/ metastatic solid tumors using NCI CTCAE toxicity grading version 5.0.</measure>
    <time_frame>5 years</time_frame>
    <description>Patients with advanced/ metastatic triple negative breast cancer, unselected for known platinum sensitivity or resistance, will be enrolled. A pilot of 10 patients will be enrolled. If 0-1 patients achieve an objective response, the combination is deemed to be of no interest for further development. If 2 or more of 10 patients achieve an objective response, another 20 patients will be enrolled to confirm the objective response rate. In the final Safety evaluations will be performed for all patients prior to each cycle of treatment, and include taking a medical history, physical examination, adverse event documentation, full blood count, renal function, liver function tests and electrocardiogram (ECG).&#xD;
Toxicities will be graded using the NCI CTCAE toxicity grading version 5.0.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Advanced Refractory Solid Tumors</condition>
  <condition>Advanced Triple Negative Breast Cancers</condition>
  <condition>Metastatic Triple Negative Breast Cancers</condition>
  <arm_group>
    <arm_group_label>Patients with refractory solid tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I will be carried out in a modified 3+3 dose escalation design, with a projected enrolment of patients with refractory solid tumors to determine the RP2D.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talazoparib</intervention_name>
    <description>Patients will be treated with Talazoparib daily on a 4 weekly cycle (28 days)</description>
    <arm_group_label>Patients with refractory solid tumors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>Patients will be treated with Selinexor once per week (3 out of 4 weeks), on a 4 weekly cycle (28 days)</description>
    <arm_group_label>Patients with refractory solid tumors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. All patients must sign an informed consent in accordance with local institutional&#xD;
             guidelines.&#xD;
&#xD;
          2. All patient must not have received prior PARPi including talazoparib&#xD;
&#xD;
          3. All patients must not have prior therapy with selinexor.&#xD;
&#xD;
          4. Age ≥ 18&#xD;
&#xD;
          5. Estimated life expectancy of at least 12 weeks.&#xD;
&#xD;
          6. Has recovered from acute toxicities from prior anti-cancer therapies to grade 2 or&#xD;
             lower.&#xD;
&#xD;
          7. a) Dose escalation phase: Patients with histologically or cytologically confirmed&#xD;
             advanced or metastatic solid tumors who have radiological evidence of progressive&#xD;
             disease on study entry that is deemed unlikely to benefit from further conventional&#xD;
             therapy, or for which no standard therapy is available.&#xD;
&#xD;
             b) Dose expansion phase: Patients with previously treated, advanced or metastatic&#xD;
             histologically or cytologically confirmed triple negative breast cancers. Patients&#xD;
             must have evidence of progressive disease on study entry after at least one line of&#xD;
             anti-cancer therapy. Patients will be stratified into platinum-naïve (not having been&#xD;
             treated with platinums-containing chemotherapy in the neoadjuvant, adjuvant or&#xD;
             palliative setting), platinum sensitive (defined as having prior objective response or&#xD;
             sustained disease control lasting ≥6 months to platinum-containing chemotherapy in the&#xD;
             metastatic setting, or relapsed ≥6 months after completing neoadjuvant or adjuvant&#xD;
             platinums-containing chemotherapy), and platinum resistant (defined as having&#xD;
             progressive disease as the best response or disease control &lt;6 months to&#xD;
             platinum-containing chemotherapy in the metastatic setting, or relapsed &lt;6 months&#xD;
             after completing neoadjuvant or adjuvant platinums-containing chemotherapy).&#xD;
&#xD;
             There is no upper limit on the number of prior treatments provided all&#xD;
             inclusion/exclusion criteria are met. Hormone ablation therapy is considered an&#xD;
             anti-cancer regimen. Radiation and surgery are not considered anti-cancer regimens.&#xD;
&#xD;
          8. Measurable disease by RECIST 1.1 criteria.&#xD;
&#xD;
          9. Eastern cooperative Oncology Group (ECOG) Performance Status of 0-1&#xD;
&#xD;
         10. Adequate bone marrow function and organ function within 2 weeks of study treatment&#xD;
&#xD;
               1. Adequate hematologic function defined as:&#xD;
&#xD;
                    -  Absolute neutrophil (segmented and bands) count (ANC) ≥ 1.5 x 109/L&#xD;
&#xD;
                    -  Platelets ≥ 125 x 109/L during dose escalation phase; platelets ≥ 100 x&#xD;
                       109/L during dose expansion phase&#xD;
&#xD;
                    -  Hemoglobin ≥ 9 x 109/L&#xD;
&#xD;
               2. Hepatic function:&#xD;
&#xD;
                    -  Bilirubin ≤ 1.5 times the upper limit of normal (ULN)&#xD;
&#xD;
                    -  ALT or AST ≤ 2.5 times ULN (or ≤ 5 times ULN with liver metastases)&#xD;
&#xD;
               3. Adequate renal function:&#xD;
&#xD;
                    -  Calculated creatinine clearance of ≥ 60 mL/min, calculated using the formula&#xD;
                       of Cockroft and Gault: (140-Age) x Mass (kg)/(72 x creatinine mg/dL);&#xD;
                       multiply by 0.85 if female.&#xD;
&#xD;
         11. Able to swallow tablets/ pills.&#xD;
&#xD;
         12. Able to comply with study-related procedures.&#xD;
&#xD;
         13. Female patients of childbearing potential must have a negative serum pregnancy test at&#xD;
             screening and agree to use highly effective methods of contraception throughout the&#xD;
             study and for 7 months following the last dose of study treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Treatment within the last 30 days with any investigational drug.&#xD;
&#xD;
          2. Concurrent administration of any other tumour therapy, including cytotoxic&#xD;
             chemotherapy, hormonal therapy, and immunotherapy&#xD;
&#xD;
          3. Major surgery within 28 days of study drug administration&#xD;
&#xD;
          4. Active infection that in the opinion of the investigator would compromise the&#xD;
             patient's ability to tolerate therapy.&#xD;
&#xD;
          5. Serious concomitant disorders that would compromise the safety of the patient or&#xD;
             compromise the patient's ability to complete the study, at the discretion of the&#xD;
             investigator.&#xD;
&#xD;
          6. Pregnancy&#xD;
&#xD;
          7. Breast feeding&#xD;
&#xD;
          8. Poorly controlled diabetes mellitus&#xD;
&#xD;
          9. Second primary malignancy that is clinically detectable at the time of consideration&#xD;
             for study enrolment (for phase II only).&#xD;
&#xD;
         10. Symptomatic brain metastasis.&#xD;
&#xD;
         11. History of significant neurological or mental disorder, including seizures or&#xD;
             dementia.&#xD;
&#xD;
         12. Unable to comply with study procedures&#xD;
&#xD;
         13. Current or anticipated use of strong P-gp inhibitors: amiodarone, carvedilol,&#xD;
             clarithromycin, cobicistat, darunavir, dronedarone, erythromycin, indinavir,&#xD;
             itraconazole, ketoconazole, lapatinib, lopinavir, propafenone, quinidine, ranolazine,&#xD;
             ritonavir, saquinavir, telaprevir, tipranavir, valspodar, verapamil&#xD;
&#xD;
         14. Current or anticipated use of strong BCRP inhibitors: curcumin, cyclosporine A,&#xD;
             eltrombopag, elacridar, fumitremorgin C, novobiocin, sulfasalazine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soo Chin Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University Hospital, Singapore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Soo Chin Lee</last_name>
    <phone>6779 5555</phone>
    <email>soo_chin_lee@nuhs.edu.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <results_reference>
    <citation>Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Trial Investigators. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018 Nov 29;379(22):2108-2121. doi: 10.1056/NEJMoa1809615. Epub 2018 Oct 20.</citation>
    <PMID>30345906</PMID>
  </results_reference>
  <results_reference>
    <citation>Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1;30(4):558-566. doi: 10.1093/annonc/mdz012.</citation>
    <PMID>30689707</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>August 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Selinexor</keyword>
  <keyword>Talazoparib</keyword>
  <keyword>breast cancer</keyword>
  <keyword>Triple negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Talazoparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

